( August 19, 2026, 1:42 PM EDT) -- NEW HAVEN, Conn. — Novo Nordisk Inc. has failed to identify any controlling law or overlooked facts warranting reconsideration of a ruling denying it summary judgment in an insulin pen product liability action, Griffin Health Services Corp. tells a Connecticut federal court in an objection to a motion for reconsideration, contending that the manufacturer is now seeking “a third opportunity to present a summary judgment argument.”...